November 3, 3009 — On Monday, Andrea Natale, M.D., FACC, FHRS, an electrophysiologist and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, became the first physician in the United States to perform an ablation procedure to treat a patient with a cardiac arrhythmia using the newly FDA-cleared CARTO 3 Navigation System. "Imaging with the new CARTO 3 System puts us at the forefront of being able to visualize and treat nearly every type of arrhythmia," Dr. Natale said. "It also reinforces our commitment to helping the growing pool of arrhythmia patients get fast, effective treatment." The CARTO 3 Navigation System is a three-dimensional imaging system that allows doctors to quickly and accurately visualize cardiac anatomy. It is especially useful in the treatment of atrial fibrillation, or AFIB. AFIB is the most common type of irregular heart rhythm in the United States, affecting an estimated 5.6 million people, and is increasing due to the rise in the aging population. Texas Cardiac Arrhythmia Institute at St. David's Medical Center offers a full range of electrophysiology procedures, including catheter ablation — for which physicians utilize the only FDA-approved catheter for treating AFIB, the NAVISTAR THERMOCOOL Irrigated Ablation Catheter. THERMOCOOL Navigation Catheters are approved (for drug refractory recurrent symptomatic paroxysmal atrial fibrillation) when used with CARTO 3 Systems. The CARTO 3 System gives doctors the ability to pinpoint the location of these catheters during ablation procedures with speed, precision and clarity. For more information: visit www.StDavids.com/sdmc.aspx
If you enjoy this content, please share it with a colleague
Texas Cardiac Arrhythmia Institute First in U.S. to Use CARTO 3 Navigation System
Related Content
April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...
April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...
Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...
July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...
July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...
June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...
May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...
May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...
February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...
January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...